To this end, a large population-based cohort study demonstrated that patients with T2DM and liver cirrhosis who were on GLP-1 RAs therapy had a markedly lower risk of mortality, cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and liver cirrhosis compared to non-GLP-1 RAs users [82]. Here, GLP1R is linked to type 2 diabetes mellitus.